Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00698230 | Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics | PHASE2 | COMPLETED | 302 | — | — | May 1, 2008 | May 1, 2009 | Feb 14, 2018 | 68 | United States, Puerto Rico |
| Arm | Type | Description |
|---|---|---|
| Treatment A - INCB013739 & Metformin | EXPERIMENTAL | INCB013739 5 mg QD and Metformin |
| Treatment B - INCB013739 & Metformin | EXPERIMENTAL | INCB013739 15 mg QD and Metformin |
| Treatment C - INCB013739 & Metformin | EXPERIMENTAL | INCB013739 50 mg QD and Metformin |
| Treatment D - INCB013739 & Metformin | EXPERIMENTAL | INCB013739 100 mg QD and Metformin |
| Treatment E - INCB013739 & Metformin | EXPERIMENTAL | INCB013739 200 mg QD and Metformin |
| Treatment F - Placebo | PLACEBO_COMPARATOR | Matching placebo |
| Name | Type | Description |
|---|---|---|
| INCB013739 | DRUG | INCB013739 5 mg QD tablet |
| Placebo comparator matching INCB013739 | DRUG | Orally once daily tablet |
| Metformin | DRUG | - |
Inclusion Criteria: * Established diagnosis of Type 2 Diabetes * Stable dose of metformin for more than 8 weeks Exclusion Criteria: * Subjects with Addison's disease or Cushing's Syndrome * Type 1 diabetes mellitus or secondary forms of diabetes * Subjects with uncontrolled thyroid disease * Hist...